It would take medicine almost 100 years to translate a Nobel Prize winner’s “magic bullet” to fight cancer into reality. Now, in the past few years, the fruits of his research have emerged as one of the hottest areas of cancer medicine… . . . and of biotech deal making.
Less than six weeks ago, on Friday, September 6, we recommended buying shares of Sagimet Biosciences (Nasdaq: SGMT). Since we published our report, Sagimet’s management has appeared at several institutional-investor conferences and has also released a fuller data set confirming its blockbuster Phase II clinical trial results for the company’s lead drug candidate denifanstat. Yesterday,
Over my decades in investing, I’ve learned the hard way that recognizing mistakes as quickly as possible, and then acting decisively to fix them – if need be, by trimming or exiting a position – is one of the cardinal attributes that separate professionals from amateurs. And so you can count on me to raise
For a variety of economic reasons, biotech has not participated in the current tech rally. And, as a result, there has likely never been a wider gap between tech stocks and biotech stocks. Right now, as we report in this week’s issue, a major biotech bull market is forming.
Our recommendation this month is a company on the vanguard of gene therapy, with several transformative medicines in its pipeline. Best of all, this company trades at a negative enterprise value, making it a compelling value – beyond its scientific promise.
This report highlights the opportunity to invest alongside the world’s most sophisticated investors at a significant discount to the prices they paid – while the company we feature is not yet a household name.
With a 64% probability of the Fed cutting interest rates in September, the macro economic environment is clearly shifting in the right direction for biotech, but even before that has happened, these two companies released blowout earnings reports.
This month’s issue of Biotech Frontiers focuses on a fast follower whose stock is poised to soar because it has a better version of a successful medicine… which it has also, strategically, chosen to make available at a better price.
In this month’s issue, we focus on a drugmaker that has one hidden asset that ties all its other assets together and acts as a value multiplier for them: and it has a spectacular track record of success that traces back to the company’s origins.
The biotech company we recommend in this issue has a solid balance sheet and features more potential catalysts to success than many other biotech opportunities. These characteristics make it particularly well-suited to the investing environment we find ourselves in today.